Merchavia Holdings and Investments Ltd
TTASE:MRHL121.40
ILA
-0.10
(-0.08%)
ISIN
IL0002570146
Return %
Stock
S&P 500
1Y
33.70
14.20
3Y
37.95
81.12
5Y
-59.40
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Semi-annual Revenue
FRC
•
in mil. unless spec.Semi-annual Earnings Per Share
FRC
•
in mil. unless spec.Semi-annual Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Eli Arad
- Full Time Employees
- 1
- Sector
- Finance
- Industry
- Financial conglomerates
- Address
- BSR Tower No. 4 Bnei Braq TA Israel 5126112
- IPO Date
- Jan 1, 1991
- Website
- merchavia.com
- Similar Companies
- Business
- Merchavia Holdings and Investments Ltd (MRHL.TA) is an Israel-based principal investment firm specializing in the med-tech, life sciences, biomedical, and medical distribution sectors; it focuses on early-stage companies targeting large markets estimated in billions of dollars, with a strategic preference for investments linked to Cleveland Clinic Ventures and encompassing areas such as wearable cardiac monitoring, digital therapeutics, blood testing diagnostics, cancer detection, pain management, cannabis delivery systems, neuromonitoring, women's health, and air quality solutions. The firm maintains a portfolio of approximately eight investments, including stakes in CardiacSense (around 5.5-5.7%, featuring a medical-grade watch for continuous atrial fibrillation detection with recent CE Mark approval in 2021 and FDA clearance for heart rate monitoring in 2024), EFA (about 7-9%, developing real-time blood count devices with ongoing milestone-based funding and a 2023 merger agreement with Molekule Group Inc.), RMDY Health (roughly 7-9%, providing digital health platforms for pharma with U.S. Fortune 500 client agreements), CDx (around 5.5%, early prostate cancer diagnostics with U.S. distribution deals), and others like Veoli (20% in medical cannabis inhalation, 2019), Wellness Layers (digital therapeutics, prior funding), and Juventas. Founded in 1972 and headquartered in BSR Tower No. 4, Bnei Brak, Israel, the company, formerly NEPCO STAR LTD which divested its jewelry operations in 2007, operates primarily in Israel with global investment exposure through portfolio firms securing distribution in India, Brazil, UAE, Europe, and the U.S. Recent developments include CardiacSense's FDA approval for its wristwatch in May 2024, completion of Cardiacsense2 experimental results processing in 2024-2025, EFA's merger with Molekule in 2023, and sustained portfolio milestones such as exclusive distribution pacts and clinical validations reported through 2024, alongside revenue of 119,000 ILS in 2024 reflecting investment-stage focus.